PERSPECTA

News from every angle

← Back to headlines

Sangamo Therapeutics Appeals Delisting While Advancing ST-920 Submission

Sangamo Therapeutics is preparing to submit its Biologics License Application (BLA) for ST-920 as early as this summer. Concurrently, the company is appealing a NASDAQ delisting decision made in June.

14 May, 22:31 — 14 May, 22:31
PostShare

Sources

Showing 1 of 1 sources
seeking-alphaMixed2h ago

Sangamo anticipates completing ST-920 BLA submission as early as this summer while appealing NASDAQ delisting in June

Read full article →

Related Stories

Oil Jumps Above $100 After US-Iran Talks Fail

just now

Polish Developers' Dividends Reach One Billion Amid Falling Rates

7m ago

India's Wholesale Inflation Jumps to 8.3% Driven by Oil and Weak Rupee

9m ago

Seoul's Kospi Index Surpasses 8,000 for First Time Amid AI Stock Boom

17m ago